Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Despite being intended as a short bonus feature of the compilation, it was considered the highlight of the collection. Its success led to the creation of the much longer and more in-depth Portal 2, which included both single player and cooperative multiplayer modes. In addition to the challenging puzzle elements, both games are praised for their dark humor, written by Erik Wolpaw, Chet Faliszek, and Jay Pinkerton, with notable voice work by actors Ellen McLain, Stephen Merchant, and J. K. Simmons. A number of spin-off media productions have been developed alongside the games, and several of the game's iconic elements have become parts of internet memes.
Taylor), in the grounds of their Oxford home (1946–47) before moving to a property she purchased in the Oxfordshire village of South Leigh (1947–49). In May 1949, the Thomas family moved back to Laugharne into The Boat House, purchased by Margaret Taylor on their behalf. In 1951 Taylor purchased a second property in Camden Town, North London on their behalf where they stayed from October 1951 – January 1952. Caitlin Thomas's autobiographies, Leftover Life to Kill (1957) and My Life with Dylan Thomas: Double Drink Story (1997), describe the effects of alcohol on their relationship: "Ours was not only a love story, it was a drink story, because without alcohol it would never had got on its rocking feet", she wrote, and "The bar was our altar." Biographer Andrew Lycett describes the relationship as one of alcoholic co-dependency and notes how deeply Caitlin resented her husband's numerous extramarital affairs. Dylan and Caitlin Thomas had three children: Llewelyn Edouard (1939–2000), Aeronwy Thomas-Ellis (1943–2009) and Colm Garan Hart (1949–2012). Llewelyn and Aeronwy were privately educated, at the Magdalen College School, Oxford and at the Arts Education School in Tring, Hertfordshire, respectively.
Betaine transporter (SLC6A12) InterPro: IPR002983 Creatine transporter (SLC6A8) InterPro: IPR002984 Dopamine neurotransmitter transporter (SLC6A3) InterPro: IPR002436 Inebriated neurotransmitter transporter InterPro: IPR002944 GABA neurotransmitter transporter GAT-1 (SLC6A1) InterPro: IPR002980 GABA neurotransmitter transporter GAT-2 (SLC6A13) InterPro: IPR002981 GABA neurotransmitter transporter GAT-3 (SLC6A11) InterPro: IPR002982 Glycine neurotransmitter transporter, type 1 (SLC6A9) InterPro: IPR003028 Noradrenaline neurotransmitter transporter (SLC6A2) InterPro: IPR002435 Orphan neurotransmitter transporter (SLC6A15) InterPro: IPR002438 Serotonin (5-HT) neurotransmitter transporter, N-terminal (SLC6A4) InterPro: IPR013086 Taurine transporter (SLC6A6) InterPro: IPR002434
Sources: en.wikipedia.org
Cohen (1952), former co-owner of the Boston Celtics and the Brooklyn Nets; former chairman and CEO of the Madison Square Garden Corporation Lawrence K. Grossman (1952), president of PBS 1976–1984 and NBC News 1985–1988 Richard Wald (1952), former president of NBC News 1973–1977 Robert A. Belfer (1955), oilman and philanthropist, namesake of the Belfer Center for Science and International Affairs at Harvard University Thomas Ludlow Chrystie II (1955), first chief financial officer of Merrill Lynch & Company and creator of the Cash Management Account Alfred Lerner (1955), chairman of MBNA Bank and ex-owner of the Cleveland Browns Richard Ravitch (1955), chairman of the Metropolitan Transportation Authority and the Bowery Savings Bank Sid Sheinberg (1955), head of Universal Pictures Barry F. Sullivan (1955), chairman and CEO of First Chicago Bank, deputy mayor of New York City under David Dinkins Edward Botwinick (1956), IT entrepreneur and inventor, co-founder of Timeplex Franklin A. Thomas (1956), former president of The Ford Foundation James R. Barker (1957), chairman of Interlake Steamship Company, former chairman and CEO of Moore-McCormack Peter L.
A wound is any disruption of or damage to living tissue, such as skin, mucous membranes, or organs. Wounds can either be the sudden result of direct trauma (mechanical, thermal, chemical), or can develop slowly over time due to underlying disease processes such as diabetes mellitus, venous/arterial insufficiency, or immunologic disease. Wounds can vary greatly in their appearance depending on wound location, injury mechanism, depth of injury, timing of onset (acute vs chronic), and wound sterility, among other factors. Treatment strategies for wounds will vary based on the classification of the wound, therefore it is essential that wounds be thoroughly evaluated by a healthcare professional for proper management. In normal physiology, all wounds will undergo a series of steps collectively known as the wound healing process, which include hemostasis, inflammation, proliferation, and tissue remodeling. Age, tissue oxygenation, stress, underlying medical conditions, and certain medications are just a few of the many factors known to affect the rate of wound healing.
== Pharmacokinetics == Absorption: Once consumed, cefuroxime axetil is converted to the active compound cefuroxime by esterases of mucosal cells in the gastrointestinal tract. Cefuroxime is then released for systematic circulation. If cefuroxime axetil is given with food, absorption values can increase from 37% in fasting patients to 52% in fed patients. Distribution: It has been reported that after cefuroxime axetil administration, it can be found in tonsil tissue, sinus tissue, bronchial tissue and middle ear effusion. Elimination: After cefuroxime production, the body is unable to metabolize the drug, and is eliminated unchanged in the urine.
Sources: en.wikipedia.org
Allergic diseases are strongly familial; identical twins are likely to have the same allergic diseases about 70% of the time; the same allergy occurs about 40% of the time in non-identical twins. Allergic parents are more likely to have allergic children and those children's allergies are likely to be more severe than those in children of non-allergic parents. Some allergies, however, are not consistent along genealogies; parents who are allergic to peanuts may have children who are allergic to ragweed. The likelihood of developing allergies is inherited and related to an irregularity in the immune system, but the specific allergen is not. The risk of allergic sensitization and the development of allergies varies with age, with young children most at risk. Several studies have shown that IgE levels are highest in childhood and fall rapidly between the ages of 10 and 30 years. The peak prevalence of hay fever is highest in children and young adults, and the incidence of asthma is highest in children under 10. Ethnicity may play a role in some allergies; however, racial factors have been difficult to separate from environmental influences and changes due to migration. It has been suggested that different genetic loci are responsible for asthma, to be specific, in people of European, Hispanic, Asian, and African origins.
That [RnO3F]− did not form in other experiments may have been due to the high concentration of fluoride used. Electromigration studies also suggest the presence of cationic [HRnO3]+ and anionic [HRnO4]− forms of radon in weakly acidic aqueous solution (pH > 5), the procedure having previously been validated by examination of the homologous xenon trioxide. The decay technique has also been used. Avrorin et al. reported in 1982 that 212Fr compounds cocrystallised with their caesium analogues appeared to retain chemically bound radon after electron capture; analogies with xenon suggested the formation of RnO3, but this could not be confirmed. It is likely that the difficulty in identifying higher fluorides of radon stems from radon being kinetically hindered from being oxidised beyond the divalent state because of the strong ionicity of radon difluoride (RnF2) and the high positive charge on radon in RnF+; spatial separation of RnF2 molecules may be necessary to clearly identify higher fluorides of radon, of which RnF4 is expected to be more stable than RnF6 due to spin–orbit splitting of the 6p shell of radon (RnIV would have a closed-shell 6s26p21/2 configuration). Therefore, while RnF4 should have a similar stability to xenon tetrafluoride (XeF4), RnF6 would likely be much less stable than xenon hexafluoride (XeF6): radon hexafluoride would also probably be a regular octahedral molecule, unlike the distorted octahedral structure of XeF6, because of the inert pair effect.
=== Biochemical === In size-exclusion chromatography, the residence time of a molecule is related to its volume, which is roughly proportional to its molecular weight. Residence times also affect the performance of continuous fermentors. Biofuel cells utilize the metabolic processes of anodophiles (electronegative bacteria) to convert chemical energy from organic matter into electricity. A biofuel cell mechanism consists of an anode and a cathode that are separated by an internal proton exchange membrane (PEM) and connected in an external circuit with an external load. Anodophiles grow on the anode and consume biodegradable organic molecules to produce electrons, protons, and carbon dioxide gas, and as the electrons travel through the circuit they feed the external load. The HRT for this application is the rate at which the feed molecules are passed through the anodic chamber. This can be quantified by dividing the volume of the anodic chamber by the rate at which the feed solution is passed into the chamber. The hydraulic residence time (HRT) affects the substrate loading rate of the microorganisms that the anodophiles consume, which affects the electrical output. Longer HRTs reduce substrate loading in the anodic chamber, which can lead to a reduced anodophile population and performance when there is a deficiency of nutrients.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.